Just a Phase
Survodutide Shows Significant Improvement in MASH and Liver Fibrosis in Phase 2 Trial
Patients taking the glucagon/glucagon-like peptide-1 receptor dual agonist survodutide saw an 83% improvement in ...
AUGUST 9, 2024
Low-Dose Aspirin Reduces Liver Fat in Patients With MASLD in Phase 2 Trial
A daily dose of aspirin led to a significant reduction in liver fat in patients with metabolic ...
AUGUST 2, 2024
Pegozafermin Shows Promise for Treating MASH
The new drug pegozafermin could offer a promising treatment for patients with metabolic ...
DECEMBER 15, 2023
Load more